The medical devices sector has underperformed in 2026 as investor capital shifted toward artificial intelligence and energy equities, leaving several industry leaders trading well below their 52-week highs despite sustained revenue growth. Fair-value models from InvestingPro indicate potential upside of 31% to 38% for targeted names, suggesting a disconnect between fundamentals and market pricing.
Boston Scientific (BSX) and Insulet (PODD) have each declined 47-48% year-to-date, even as their revenues rose 13.5% and 29.4%, respectively. Intuitive Surgical (ISRG) has fallen 33.1% this year despite 20.7% revenue growth, while Stryker (SYK) is down just 5.8% with 8.5% revenue expansion. The sector's broader selloff has created valuation gaps, with InvestingPro estimating fair-value targets exceeding current prices by significant margins.
Among the most pronounced opportunities, InMode (INMD) trades at $15.08 with a forward price-to-earnings ratio of 11.0x and a fair-value estimate of $20.85, implying 38.3% upside. Insulet (PODD) follows with a 34.5% potential gain to its $196.45 target, despite a 29.4% revenue increase. Align Technology (ALGN) and Boston Scientific (BSX) are projected to gain 33.3% and 31.5%, respectively, while Globus Medical (GMED) offers 31.1% upside to its $110.81 target. ResMed (RMD), the sector's defensive anchor, has declined just 3.1% this year and yields 1.1%.
Humacyte (HUMA) has provided a near-term catalyst, announcing plans to file for FDA approval of its dialysis access device in November 2026. Metall Zug (METN) reported profitability in its medical devices unit, further underscoring pockets of resilience within the sector. Analysts note that the valuation disconnect reflects broader market rotation rather than fundamental deterioration in the medical devices industry.
The sector's small-cap segment, exemplified by InMode (INMD), has also drawn attention. With a market capitalization of $866 million and a financial health score described as "Great," InMode stands out despite a 6.7% revenue decline attributed to cyclical weakness in aesthetic procedures. Boston Scientific, with a $73 billion market cap, remains a focal point, with consensus targets indicating 21.6% upside from current levels.
